Health technology assessment (HTA) is the process of evaluating the added value of new medicines and technologies relative to existing therapies. Now, the European Commission is strengthening cross-border cooperation and making it possible for EU countries to use common HTA methodologies and procedures. The goal is to ensure quicker access to innovative health technologies, increase the transparency of value assessments, avoid duplication of work for national HTA bodies, and improve business predictability for manufacturers. In July, more than 300 stakeholders met in Brussels to discuss future HTA cooperation, including the importance of engaging patients and clinicians early and the potential of the EU’s Digital Single Market to enable sharing of disease registry and real-world data across country borders.
